This trial evaluates the combination of an anti-PD-L1 antibody (avelumab) with a CDK4/6 kinase inhibitor (palbociclib) and hydroxychloroquine (HCQ) in patients with HR+ early-stage BC. Here, CD274 is linked to breast cancer.